Phase 3 Oesophageal Cancer Trial, Recruiting NCT03731442 Sponsor: Chinese Academy of Medical Sciences Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Phase 3 Oesophageal Cancer Trial, Recruiting

NCT03731442
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • The cancer has come back in or near the area where it was originally treated (called a locoregional recurrence) after major surgery to remove it
  • The surgeon was unable to remove all of the cancer during surgery (known as a positive resection margin, or R1/R2 result)
  • The cancer has come back in an area that was not covered by previous radiation treatment given after surgery
  • The cancer has come back after chemotherapy that was given following surgery
  • No treatment has been received for the cancer since it came back
  • People aged between 16 and 70 years old
  • People who are generally able to carry out most daily activities (a performance score above 70 on the Karnofsky scale — confirm with trial site if unsure what this means)
  • No history of allergic reactions to medications
  • The liver and kidneys are working well enough (confirm with trial site for specific thresholds)
  • A white blood cell count above 4.0 × 10⁹/L, which is a measure of immune system health

Who may not be able to join:

  • People who are older than 70 or younger than 16 years of age
  • People who are currently pregnant or breastfeeding
  • People who have a history of allergic reactions to medications
  • People who do not wish to give their informed consent to participate
  • People whose liver or kidney function is not at a sufficient level, or whose blood count results are abnormal
  • People with serious heart or blood vessel conditions, active infections, active stomach or intestinal ulcers, diabetes with poorly controlled blood sugar levels, or mental health disorders

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86-13621018159

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Chinese Academy of Medical Sciences
Registry
ClinicalTrials.gov
Start date
1 November 2018
Est. completion
31 October 2022

Where this trial is recruiting

🇨🇳 China

Primary endpoints

1-, 2-, 3-year overall survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov